Development of time‐resolved fluoroimmunoassay with enhanced fluorescence reaction for the quantitation of atezolizumab in plasma

Abstract

Atezolizumab (ATZ) is a human monoclonal antibody, which has been granted multiple approvals from the US Food and Drug Administration (FDA) for the immunotherapy of different types of cancer. This study describes the prototype of a time‐resolved fluoroimmunoassay (TRFIA) for the quantitation of ATZ in plasma. The assay involved the non‐competitive binding of ATZ to its specific antigen [programmed death‐ligand 1 (PD‐L1) protein]. The immune complex formed on the inner surface of the assay plate wells was quantified by anti‐human secondary antibody labeled with a chelate of europium‐ethylenediaminetetraacetic acid. The enhanced fluorescence signal was generated by an enhanced fluorescence solution composed of thenoyltrifluoroacetone, trioctylphosphine oxide, and Triton X‐100. The conditions of the TRFIA were refined, and its optimum procedures were established. The assay was validated in accordance with the immunoassay validation guidelines, and all the validation parameters were acceptable. The working range of the assay was 20–1000 pg mL−1, and its limit of quantitation was 20 pg mL−1. The assay was applied to the quantitation of ATZ in plasma samples with satisfactory accuracy and precision. The proposed TRFIA has significant benefits over the existing methodologies for the quantitation of ATZ in clinical settings.